Why Zimmer Biomet Stock Sank After a Q1 Earnings Beat and Raised Profit Outlook

Zimmer Biomet dropped roughly 9% Tuesday, despite topping first-quarter expectations and bumping up its 2026 profit outlook. Investors zeroed in on a flat sales forecast, a CFO departure, and hints of pressure from a revamp of U.S. sales operations. Shares were changing hands at $84.17 late in the morning.